Shine a Light on Diabetic Nerve Pain? A Sham-Controlled Trial Tests the Idea

Could a few minutes of laser treatment each day help relieve the burning, tingling, and persistent foot pain associated with diabetic neuropathy? A randomized, double-blind, sham-controlled trial suggests that laser therapy for diabetic neuropathy may offer meaningful short-term pain relief. However, reducing pain is not the same as repairing damaged nerves.

Published October 11, 2026, in Pain Research and Management, the study examined whether a home-use, dual-wavelength laser device could improve painful diabetic peripheral neuropathy (DPN). Its findings offer clinicians another potential approach for patients whose symptoms remain difficult to manage.

Table of Contents

• How dual-wavelength laser therapy was tested
• What the clinical trial found
• How laser treatment compares with established therapies
• What the findings mean for clinical practice
• Conclusion
• Frequently Asked Questions

How Was Laser Therapy for Diabetic Neuropathy Tested?

Researchers conducted a prospective clinical trial involving 64 adults with painful diabetic peripheral neuropathy at four independent clinical sites across the United States.

Participants were randomly assigned to active laser treatment or a sham device designed to resemble treatment without delivering the therapeutic laser exposure.

The active group included 33 participants, while 31 received sham treatment. Both participants and study evaluators were blinded to treatment assignments.

The device used two wavelengths of light at the same time: 640-nanometer red light and 405-nanometer violet light. This approach, commonly called low-level laser therapy or photobiomodulation, uses light energy without the tissue-heating effects associated with surgical lasers.

Participants completed two daily treatment sessions for three weeks, spending five minutes on each foot per session.

Importantly, participants maintained their existing pain medication regimens. Therefore, researchers evaluated laser treatment as an additional intervention rather than a replacement for standard care.

The primary outcome was clinically meaningful pain relief, defined as a reduction of at least 30% on a 100-point visual analog pain scale.

Researchers also assessed neuropathic symptoms, patient satisfaction, treatment adherence, safety, and whether improvements persisted after treatment ended.

What Did the Sham-Controlled Laser Therapy Trial Find?

The trial reported a statistically significant improvement in pain among participants receiving active treatment.

After three weeks, 72.7% of participants in the active group achieved at least a 30% reduction in pain, compared with 32.3% in the sham group.

This represented a difference of approximately 40.5 percentage points between groups, with a statistically significant result (p = 0.0024).

Additionally, mean pain scores declined by 33.4 points with active treatment, compared with 20.0 points among sham-treated participants.

These results suggest that the laser treatment provided more pain relief than the sham device.

However, the sham group also experienced substantial pain relief. This response highlights the importance of controlled trials when evaluating treatments involving subjective symptoms.

Did Pain Relief Continue After Treatment?

Participants were followed through week seven, four weeks after the three-week treatment period ended.

Researchers found that pain improvements generally persisted in the active-treatment group during this follow-up period.

Furthermore, symptom assessments suggested greater improvement in burning pain, sudden episodes of pain, and abnormal sensations such as tingling.

In contrast, stimulus-evoked pain, including discomfort triggered by touch, did not demonstrate a clear treatment advantage.

Patients who received laser treatment also reported greater satisfaction. No serious device-related adverse events were reported.

Nevertheless, these findings reflect a relatively small trial with limited follow-up. They cannot establish whether improvements would persist for several months or years.

The study was also sponsored by device manufacturer Erchonia Corporation. Consequently, independent replication would strengthen confidence in the results.

The full findings are available in the published randomized clinical trial.

How Does Laser Therapy Compare With Established Neuropathy Treatments?

Current guidelines emphasize medications with established evidence for reducing painful diabetic neuropathy.

The American Diabetes Association Standards of Care in Diabetes 2026 recommend several initial medication classes, including gabapentinoids, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, and sodium channel blockers.

Common treatment options include pregabalin (Lyrica), duloxetine (Cymbalta), and gabapentin (Neurontin).

These medications can reduce neuropathic pain, although patients may experience dizziness, sedation, or other adverse effects.

Additionally, an 8% topical capsaicin patch (Qutenza) offers an FDA-approved option for painful diabetic peripheral neuropathy of the feet.

For patients with incomplete symptom control, clinicians may consider combining treatments from different medication classes.

Individualized treatment decisions remain essential because patients differ in their symptoms, medical histories, treatment responses, and tolerance of side effects.

Laser therapy could eventually provide an additional nonpharmacological option. However, this study did not directly compare laser treatment with pregabalin, duloxetine, gabapentin, or topical capsaicin.

Therefore, its results cannot establish that laser treatment is superior or equivalent to these therapies.

Does Laser Treatment Repair Damaged Nerves?

One distinction is particularly important: pain relief does not necessarily indicate nerve regeneration.

Diabetic peripheral neuropathy involves nerve injury associated with metabolic, vascular, and inflammatory changes.

Although photobiomodulation may influence biological processes involved in pain signaling, the present trial primarily measured symptoms rather than structural nerve recovery.

Researchers did not establish improved nerve conduction, restored nerve fibers, or reversal of underlying neuropathy.

Moreover, improvements in burning pain or tingling do not necessarily mean that nerve function has returned to normal.

Accordingly, claims that laser treatment reverses diabetic neuropathy would go beyond the available evidence.

What Do These Findings Mean for Clinical Practice?

These findings suggest that laser treatment for painful diabetic neuropathy deserves further clinical investigation.

For patients experiencing persistent burning or tingling despite medication, a supervised, home-use treatment could be appealing.

However, clinicians should explain that evidence currently supports short-term symptom reduction with the specific device and treatment protocol studied.

Larger independent trials are needed to evaluate long-term effectiveness, treatment frequency, cost-effectiveness, and results across more diverse patient populations.

Importantly, reducing pain must not replace routine foot examinations, protective footwear, glucose management, or screening for loss of protective sensation.

Patients can experience less pain while remaining vulnerable to unnoticed injuries and diabetic foot complications.

Clinicians should continue comprehensive diabetes management and follow established neuropathy care recommendations when considering emerging therapies.

Conclusion

A randomized, sham-controlled trial found that dual-wavelength low-level laser treatment significantly reduced painful diabetic neuropathy symptoms over three weeks, with improvement continuing through a short follow-up period.

The results are encouraging, particularly for patients seeking additional relief beyond medication alone.

However, the study does not show that laser therapy repairs damaged nerves, provides lasting relief, or works better than established treatments.

For now, laser treatment is best viewed as a potentially useful complementary option that requires further independent research.

Frequently Asked Questions

1. Does laser therapy help relieve diabetic neuropathy pain?

A randomized trial found greater short-term pain relief with active dual-wavelength laser treatment than sham treatment. However, larger independent studies are needed to confirm effectiveness and long-term benefits.

2. Can low-level laser therapy reverse diabetic nerve damage?

No clinical evidence from this trial demonstrates reversal of nerve damage. Researchers measured pain reduction and symptom improvement, not restored nerve structure or function.

3. Is laser treatment safer than neuropathy medication?

The study reported no serious device-related adverse events. However, its small sample and short follow-up cannot establish long-term comparative safety against established medications.

4. Can patients stop taking pregabalin or duloxetine after laser treatment?

No. Participants continued their existing pain treatment during the trial. Medication changes should be made only under the supervision of a qualified healthcare professional.

5. Is laser therapy now a standard treatment for diabetic peripheral neuropathy?

Not currently. Although the studied device has received FDA marketing clearance for temporary pain relief, laser treatment is not among the ADA's recommended initial medication treatments. More evidence is needed to determine its role in routine care.

Medical Disclaimer: This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.